- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Articles for the Week of July 17
The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of July 17, 2017.
Transcript:
Hi, I’m Kelly Davio for the Center for Biosimilars, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars. Here are our top 5 biosimilars articles for the week of July 17:
Number 5: A new report shows that most US-based health plans now cover at least 1 of the 2 available FDA-approved biosimilars.
Number 4: A phase 3 trial of the proposed rituximab biosimilar candidate GP2013 shows positive results in patients with follicular lymphoma.
Number 3: Molly Billstein Leber, manager of Medication Policy and Formulary Management for the Yale New Haven Health System, discusses the FDA’s Oncologic Drugs Advisory Committee’s unanimous recommendation of approval for biosimilars to Avastin and Herceptin.
Number 2: At this week’s public meeting on the Hatch-Waxman Amendments, FDA Commissioner Dr Scott Gottlieb announced the upcoming publication of 2 documents related to the ANDA process.
And finally, Number 1: The FDA Reauthorization Act may proceed to a Senate vote sooner rather than later after the failure of the Better Care Reconciliation Act.
Read these articles and more at centerforbiosimilars.com
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.
